Compare Incyte Corporation (INCY) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock

Incyte Corporation (INCY) offers the better valuation at 15.8x trailing P/E (13.4x forward), making it the more compelling value choice. Analysts rate Incyte Corporation (INCY) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 15.8x versus Regeneron Pharmaceuticals, Inc. at 18.8x. On forward P/E, Incyte Corporation is actually cheaper at 13.4x.

Over the past 5 years, Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of +69.8%, compared to +27.2% for Incyte Corporation (INCY). A $10,000 investment in REGN five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +104.7% versus INCY's +37.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc. (REGN) is the lower-risk stock at 0.58β versus Incyte Corporation's 0.61β — meaning INCY is approximately 6% more volatile than REGN relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus 25.0% for Incyte Corporation — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INCY leads at 26.1% versus 25.7% for REGN. At the gross margin level — before operating expenses — INCY leads at 91.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Incyte Corporation (INCY) trades at 13.4x forward P/E versus 17.3x for Regeneron Pharmaceuticals, Inc. — 3.8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for REGN: 9.7% to $857.17.

In this comparison, REGN (0.4% yield) pays a dividend. INCY does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc. (REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.58), +104.7% 10Y return). Both have compounded well over 10 years (REGN: +104.7%, INCY: +37.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: INCY is a mid-cap deep-value stock; REGN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.